T2DM patients have alterations of the autonomic nervous system, as result of cardiac autonomic neuropathy. However, T2DM diagnosis and autonomic dysfunction assessed by HRV alterations predicted VVS recurrence (Diabetes Research and Clinical Practice)
Diabetes News
Category: Cardiovascular
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
The first interim analysis from EMPRISE showed that compared with sitagliptin, the initiation of empagliflozin was associated with a decreased risk of HHF among patients with T2D as treated in routine care, with and without a history of cardiovascular disease (Circulation)
Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks Findings From the Swedish National Diabetes Registry
Support for preventing delaying onset (Circulation)
Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction
A Sub-analysis From DECLARE TIMI-58 Trial (Circulation)
Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis
There continues to be a high prevalence of CVD among people with Type 2 diabetes and a high level of unmet need for risk factor control. This implies substantial scope for reducing the excess risk of CVD in diabetes through improved management of known risk factors (Diabetic Medicine)
Clinical factors associated with the recovery of cardiovascular autonomic neuropathy in patients with type 2 diabetes mellitus
Younger age was the most important factor in CAN recovery in subjects with type 2 diabetes, including recovery from the definite or severe stage. HbA1c reduction, body weight reduction, no concurrent micro/macroalbuminuria, and shorter duration of diabetes were also significantly associated with CAN recovery (Cardiovascular Diabetology)
Coronary microvascular dysfunction is associated with poor glycemic control amongst female diabetics with chest pain and non-obstructive coronary artery disease
Poor glycemic control is associated with coronary microvascular dysfunction amongst female diabetics presenting with chest pain and non-obstructive CAD. These findings highlight the importance of sex specific risk stratification models and treatment strategies when managing cardiovascular risk amongst diabetics (Cardiovascular Diabetology)
Glycemic Variability Is a Powerful Independent Predictive Factor of Midterm Major Adverse Cardiac Events in Patients With Diabetes With Acute Coronary Syndrome
A GV cutoff value of >2.70 mmol/L was the strongest independent predictive factor for midterm MACE in patients with diabetes and ACS (Diabetes Care)
Heart failure among people with Type 2 diabetes mellitus: real‐world data of 289 954 people from a diabetes database
Heart failure is common in diabetes mellitus, but the prevalence in the DPV is lower frequent than expected. The reason for improved metabolic control in heart failure may be intensified therapy with insulin, lipid‐lowering medication and anti‐hypertensives in this cohort (Diabetic Medicine)
Heart failure among people with Type 2 diabetes mellitus: real‐world data of 289 954 people from a diabetes database
Heart failure is common in diabetes mellitus, but the prevalence in the DPV is lower frequent than expected. The reason for improved metabolic control in heart failure may be intensified therapy with insulin, lipid‐lowering medication and anti‐hypertensives in this cohort (Diabetic Medicine)
Cardiovascular outcome trials of glucose-lowering medications: an update
In summary, taking into account the findings from these new studies, it is suggested that a GLP-1RA should be offered to all people with CVD and type 2 diabetes, and SGLT2 inhibitors should be prescribed for those at high risk of heart failure or with progressive decline in eGFR. DPP4 inhibitors are a safe choice within the glucose-lowering stepped algorithm (Diabetologia)
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
Empagliflozin on top of metformin treatment significantly improved arterial stiffness compared to metformin in T1DM patients. Endothelial function was similarly improved in all treatment groups (Cardiovascular Diabetology)
Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)
The global burden of microvascular and macrovascular complications is substantial in these patients with type 2 diabetes who are relatively early in the disease process. These findings highlight an opportunity for aggressive early risk factor modification, particularly in regions with a high prevalence of complications (Cardiovascular Diabetology)
Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery
Diabetic and non-diabetic patients have similar in-hospital mortality rates. Survival rates of diabetic patients start to deteriorate 3 year after surgery. Type 2 DM is an independent predictor for long-term mortality after isolated CABG surgery. Mortality is even higher when the diabetes treatment strategy included insulin (Cardiovascular Diabetology)
Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
We propose the introduction of UDCI as a standardised terminology, and call for a concerted effort to increase awareness of this condition and its consequences. By so doing, it should be possible to define the correct screening programme to facilitate early and appropriate treatment of patients with T2D and to minimise adverse CV outcomes (Cardiovascular Diabetology)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
Among adults with type 2 diabetes and high CV and renal risk, linagliptin added to usual care compared with placebo added to usual care resulted in a noninferior risk of a composite CV outcome over a median 2.2 years (JAMA)
Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial)
Renal biomarkers informing various aspects of kidney function may further our understanding of the complex interplay between diabetic kidney disease and cardiovascular disease (American Journal of Cardiology)
The association between diabetes mellitus and reduction in myocardial glucose uptake: a population-based 18F-FDG PET/CT study
Diabetes is associated with decreased myocardial glucose metabolism, which is mediated by multiple metabolic abnormalities (BMC Cardiovascular Disorders)
Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes
In conclusion, optimal glucose target levels and treatment regimens in this setting of patients are still under debate. Future studies on intensive glucose control must be developed to reduce both glucose variability and risk of hypoglycemia, thus achieving an optimal blood glucose concentration in critically ill patients, particularly in ACS (Journal of Diabetes Research)
Early vascular parameters in the micro- and macrocirculation in type 2 diabetes
These data suggest that at similar blood pressure capillary rarefaction in the retinal circulation (ICD), decreased eGFR in the renal circulation and increased central pulse pressure (cPP) of large arteries are earlier detectable than other vascular remodeling parameters of the micro- (WLR, RCF, UACR) and macrocirculation (cSBP) in patients with T2DM (Cardiovascular Diabetology)
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 12
- Next Page »
Glycosmedia is also available as an App: